Gentle combination therapy for frail myeloma patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been newly diagnosed with multiple myeloma and have had 1 or fewer cycles of treatment so far.
- You must be considered 'ultra-frail' based on a special myeloma health score (called the IMWG frailty score) that your doctor can calculate.
- If you could become pregnant (or cause a pregnancy), you must agree to use birth control and follow the study's safety program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study tests a combination of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) for people with multiple myeloma who also have moderate liver problems. The goal is to see if this combination is safe and works well for them.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.